Status:
UNKNOWN
Hyperimmune Plasma in Patients With COVID-19 Severe Infection
Lead Sponsor:
University of Catanzaro
Collaborating Sponsors:
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Azienda Sanitaria Provinciale Di Catanzaro
Conditions:
COVID-19
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Passive immunotherapy through plasma infusion of convalescent subjects - convalescent plasma - or "hyperimmune" plasma was one of the most widespread and effective anti-infective treatments in the pre...
Detailed Description
Passive immunotherapy through plasma infusion of convalescent subjects - convalescent plasma - or "hyperimmune" plasma was one of the most widespread and effective anti-infective treatments in the pre...
Eligibility Criteria
Inclusion
- inclusion criteria for donors: null-gravid, with a negative history of transfusion of blood components; possibility to sign the informed consent
- inclusion criteria for Covid-19 infected patients: serious Covid-19 infection, possibility to sign the informed consent (also through the legal tutor)
Exclusion
- exclusion criteria for donors: presence of pregnancy, recent history of transfusion of blood components, \< 18 years.
- exclusion criteria for Covid-19 infected patients: non serious Covid-19 infection, impossibility to sign the informed consent (also through the legal tutor)
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 15 2021
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04385043
Start Date
May 1 2020
End Date
May 15 2021
Last Update
May 12 2020
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Policlinico Mater Domini
Catanzaro, Italy, 88100
2
Azienda Ospedaliera Pugliese Ciaccio Catanzaro
Catanzaro, Italy, 88100
3
Azienda Ospedaliera Annunziata
Cosenza, Italy, 87100
4
Azienda Sanitaria Provinciale
Crotone, Italy, 88900